HBV

Chronic Hepatitis B Virus Infection Pipeline Market Research Report 2022: Comprehensive Insights About 40+ Companies and 40+ Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 16, 2022
Health, Infectious Diseases, Tenofovir disoproxil, HBV, Safety, Degenerative disease, Patient, News, N-Acetylgalactosamine, IIA, RNA interference, Therapy, Hepatocyte, Sirna, HBsAg, Discovery, Clinical trial, Hepatitis B, II, DA, III, Immune system, NA, Hepatitis, RNA, Vaccine, Pharmaceutical industry

The "Chronic Hepatitis B Virus Infection - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Hepatitis B Virus Infection - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The "Chronic Hepatitis B Virus Infection - Pipeline Insight, 2022," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Chronic Hepatitis B Virus Infection pipeline landscape.
  • This segment of the Chronic Hepatitis B Virus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The companies which have their Chronic Hepatitis B Virus Infection drug candidates in the mid to advanced stage, i.e.

OliX Pharmaceuticals Presents Potential Utility of GalNAc-asiRNA Platform at OPT Congress

Retrieved on: 
Wednesday, March 16, 2022
Biotechnology, Pharmaceutical, Genetics, Health, RNA interference, KOSDAQ, Therapy, HBV, Technology, NASH, Non-alcoholic fatty liver disease, Institute of Liver and Biliary Sciences, ISCB Senior Scientist Award, AMD, Disorder, Company, Congress, Hypertrophic scar, Neuropathic pain, RNA, Vaccine

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that Behfar Ardehali, Ph.D., Senior Scientist of the Company, presented at the 7th Annual OPT Congress Oligonucleotide & Precision Therapeutics.

Key Points: 
  • OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that Behfar Ardehali, Ph.D., Senior Scientist of the Company, presented at the 7th Annual OPT Congress Oligonucleotide & Precision Therapeutics.
  • The OPT Congress is being held both in-person and virtually March 15-16, 2022.
  • At the congress, Dr. Ardehali discussed the potential utility of GalNAc-asiRNA platform for treatment of liver diseases and presented the Companys latest advancements in liver programs, including Nonalcoholic steatohepatitis (NASH) and HBV.
  • OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights

Retrieved on: 
Thursday, March 10, 2022
VBR, C1-inhibitor, U.S. Securities and Exchange Commission, Securities Act of 1933, Antiviral Research, Therapy, HBV, Degenerative disease, Report, AbbVie, Program, Safety, Development, Drug Quality and Security Act, Assembly, ICAR, Asilomar International Conference on Climate Intervention Technologies, Sumathi Best Television Current Reporting Award, DNA, Securities Exchange Act of 1934, GLOBE, Doctor of Philosophy, Patient, SEC, Research, ATM, Annual report, Conference, MD, Treatment, BeiGene, 2021 Essex County Council election, CccDNA, Liver, Initiate, Acquisition, COVID-19, Hepatitis B virus, AO, SAN, AASLD, Pharmaceutical industry, Allergan

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.
  • We look forward to introducing the first of these during a web event at the end this month.
  • Revenues from collaborative research were $6.3 million for the year ended December 31, 2021, compared to $79.1 million in 2020.
  • Research and development expenses were $68.5 million for the year ended December 31, 2021, compared to $106.8 million in 2020.

Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, March 10, 2022
Nasdaq, Safety, COVID, RNA transfection, Drug development, CAMS, CHB, Private Securities Litigation Reform Act, Research, U.S. Securities and Exchange Commission, Therapy, NASH, Chief executive officer, Investment, HBV, Oligonucleotide, Fatty liver disease, DNA, Forward-looking statement, THR, Mab, Hyperlipidemia, MBA, GLOBE, Net, Doctor of Philosophy, SAD, Patient, Institute of Liver and Biliary Sciences, HBsAg, Security (finance), Viral hepatitis, Technology, Terminology, Hepatitis, G&A, COVID-19, PD-1, HVS, Hepatitis B virus, Growth, PK, Administration, HV, Nivolumab, Program, Degenerative disease, RNA, ASO, CEO, R, Liver disease, Cryptocurrency, Pharmaceutical industry, Fine chemical, Vaccine, Jacob Aligo, Merck

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced its financial results for the fourth quarter and full year 2021 and provided an overview of recent business highlights.

Key Points: 
  • "Last year was very productive for our team, said Lawrence Blatt, PhD, MBA, Chairman & CEO of Aligos.
  • These approaches are well adapted to silencing transcripts important in driving the pathogenesis seen in CHB and NASH.
  • Currently, the 10 mg dose level is being evaluated in HBeAg-negative subjects to better define the dose-response characteristics of ALG-000184.
  • We plan to conduct longer term studies (12 weeks) later this year and share these data at a scientific conference in H2 2022.

HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology

Retrieved on: 
Tuesday, March 8, 2022
NASDAQ, Immune tolerance, Safety, Head, Biomarker, AACR, Clinical trial, Lung, HIV, Gilead, Mouse, Private Securities Litigation Reform Act, Annual report, Infection, Cell, Data, U.S. Securities and Exchange Commission, Cancer, HNSCC, HBV, Prostate cancer, NEW, Form 10-K, KRAS, DNA, Risk, GLOBE, CD8, Patient, RECIST, Offering, Neoplasm, American Association, HPV16, 2021 Essex County Council election, TCR, Arenavirus, PD-1, Standard of care, Lymphocytic choriomeningitis, Association, Poster, Medical imaging, Pharmaceutical industry, Vaccine

The AACR posters provide a broad preclinical, translational, and clinical biomarker dataset highlighting the versatility and therapeutic utility of replicating arenavirus vectors to activate and augment tumor-specific CD8+ T cell responses for tumor killing.

Key Points: 
  • The AACR posters provide a broad preclinical, translational, and clinical biomarker dataset highlighting the versatility and therapeutic utility of replicating arenavirus vectors to activate and augment tumor-specific CD8+ T cell responses for tumor killing.
  • Specifically, the data support the potential of arenaviral vectors to target self and non-self tumor antigens and be used as monotherapy or in combination with other modalities.
  • The data demonstrate one strategy to unlock the potential of arenavirus vector-induced CD8+ T cell responses for tumor killing in a combination therapy with 4-1BB agonists.
  • HB-201 and HB-202 are HOOKIPAs lead oncology candidates engineered with the companys proprietary replicating arenaviral vector platform.

Enanta Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

Retrieved on: 
Tuesday, March 8, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Hepatitis B virus, Respiratory syncytial virus, Research, View, RSV, AbbVie, Webcast, Degenerative disease, Institute of Liver and Biliary Sciences, COVID-19, Conference, Glecaprevir/pibrentasvir, Medication, HBV, HCV, Drug discovery, Severe acute respiratory syndrome coronavirus 2, Human, NASDAQ, Pharmaceutical industry

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will give a corporate presentation at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022, at 4:40 p.m.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will give a corporate presentation at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022, at 4:40 p.m.
  • A live webcast of the event will be accessible by visiting the Events and Presentations section on the Investors page of Enantas website at www.enanta.com .
  • A replay of the webcast will be available following the event and will be archived for 30 days.
  • Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.

Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference

Retrieved on: 
Monday, March 7, 2022
Genomics, CMO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Precision medicine, Patient, Fatty liver disease, Response, HCC, Hepatocellular carcinoma, Cirrhosis, Food, Cyclophilin, Lipidomics, Liver disease, Ill, HEPA, Fast Track, Company, Artificial intelligence, Conference, Metabolomics, NASH, Proteomics, HBV, IND, HCV, HDV, GLOBE, NASDAQ, Pharmaceutical industry, Omics

EDISON, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), announced today that its CMO, Dr. Todd Hobbs, will present at the Q1 Investor Summit Conference on Wednesday, March 9, 2022 at 1:15 p.m. Eastern Time.

Key Points: 
  • EDISON, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), announced today that its CMO, Dr. Todd Hobbs, will present at the Q1 Investor Summit Conference on Wednesday, March 9, 2022 at 1:15 p.m. Eastern Time.
  • The virtual presentation will be broadcast live and archived on the Companys website at www.hepionpharma.com under Events in the Investors section.
  • The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes.
  • In November 2021, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for rencofilstat for the treatment of NASH.

Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 3, 2022
Investment, World, RNA, Assembly, Hepatitis B, COVID-19, Hepatitis, Cornerstone, Partnership, Nasdaq, CccDNA, Patent, CFBV, Method, Therapy, RNA interference, Company, Clinical trial, District, Virology, Severe acute respiratory syndrome coronavirus 2, World Health Organization, HBsAg, Research, Peripheral neuropathy, Douglas v. U.S. District Court ex rel Talk America, MRNA-1273, Degenerative disease, Sale, HBV, VBR, Coronavirus, Immune system, NA, Patient, Hospital, Safety, LNP, Membrane protein, Travel, Arbutus, District court, GLOBE, Vaccine, Pharmaceutical industry, Construction, Geneve 9640, Vaccitech, IND, Roivant Sciences, Tenofovir disoproxil

WARMINSTER,Pa., March 03, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its fourth quarter and year end 2021 financial results and provides pipeline updates.

Key Points: 
  • WARMINSTER,Pa., March 03, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its fourth quarter and year end 2021 financial results and provides pipeline updates.
  • 2021 was a transformative year for Arbutus as we greatly expanded our development efforts in Hepatitis B and coronavirus infections, including SARS-CoV-2, said William Collier, Arbutus President and Chief Executive Officer.
  • Arbutus has commenced IND-enabling studies for AB-101 and intends to complete those studies in the second half of 2022.
  • Arbutus, and Genevant, do not seek an injunction or otherwise seek to impede the sale, manufacture or distribution of MRNA-1273.

HOOKIPA Pharma Announces Pricing of $75.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

Retrieved on: 
Wednesday, March 2, 2022
808, Private Securities Litigation Reform Act, Annual report, Attention, Form S-3, Security (finance), Vesey Street, No, U.S. Securities and Exchange Commission, CD8, Offering, SVB Leerink, LLC, Telephone, Equity capital markets, Gilead, Sale, SEC, Form, Cancer, Arenavirus, State Street, HIV, Prostate cancer, HBV, RBC Capital Markets, Lung, KRAS, Risk, Nasdaq, Exercise, GLOBE, Prospectus, NASDAQ, Form 10-K

The public offering price of each share of common stock is $2.00 and the public offering price of each share of non-voting Series A-1 preferred stock is $2,000 (each share of non-voting Series A-1 preferred stock is convertible into 1,000 shares of common stock).

Key Points: 
  • The public offering price of each share of common stock is $2.00 and the public offering price of each share of non-voting Series A-1 preferred stock is $2,000 (each share of non-voting Series A-1 preferred stock is convertible into 1,000 shares of common stock).
  • HOOKIPA has granted the underwriters a 30-day option to purchase up to an additional 5,625,000 shares of its common stock at the public offering price of the common stock, less underwriting discounts and commissions.
  • The gross proceeds to HOOKIPA from this offering are expected to be $75.0 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters option to purchase additional shares.
  • All of the securities in the Offering are to be sold by HOOKIPA.

HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

Retrieved on: 
Tuesday, March 1, 2022
808, Private Securities Litigation Reform Act, Annual report, Attention, Form S-3, Security (finance), Vesey Street, No, U.S. Securities and Exchange Commission, CD8, Offering, SVB Leerink, LLC, Telephone, Equity capital markets, Gilead, Sale, SEC, Form, Cancer, Arenavirus, State Street, HIV, Prostate cancer, HBV, RBC Capital Markets, Lung, KRAS, Risk, Nasdaq, GLOBE, Prospectus, NASDAQ, Form 10-K

HOOKIPA also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the Offering, including the shares of common stock underlying the non-voting Series A convertible preferred stock.

Key Points: 
  • HOOKIPA also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the Offering, including the shares of common stock underlying the non-voting Series A convertible preferred stock.
  • All of the securities in the Offering are to be sold by HOOKIPA.
  • SVB Leerink and RBC Capital Markets are acting as joint book-running managers of the Offering.
  • The securities described above are being offered by HOOKIPA pursuant to a shelf registration statement on Form S-3 (No.